Related Experiment Video

Updated: Aug 5, 2025

Combined Use of Tail Vein Metastasis Assays and Real-Time In Vivo Imaging to Quantify Breast Cancer Metastatic Colonization and Burden in the Lungs
10:32

Combined Use of Tail Vein Metastasis Assays and Real-Time In Vivo Imaging to Quantify Breast Cancer Metastatic Colonization and Burden in the Lungs

Published on: December 19, 2019

11.0K

Targeting YAP/TAZ in Combination with PD-L1 Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer (NSCLC)

Kostas A Papavassiliou1, Georgios Marinos2, Athanasios G Papavassiliou3

  • 1First University Department of Respiratory Medicine, "Sotiria" Hospital, Medical School, National and Kapodistrian University of Athens, 11527 Athens, Greece.

Cells
|March 29, 2023
PubMed

Insights

New research highlights the role of YAP/TAZ proteins in non-small cell lung cancer (NSCLC) immune evasion. Targeting these proteins alongside immune checkpoint inhibitors may improve NSCLC treatment outcomes.

Area of Science:

  • Oncology
  • Molecular Biology
  • Immunology

Background:

  • Survival for non-small cell lung cancer (NSCLC) patients has improved with immune checkpoint inhibitors.
  • However, resistance to these therapies limits their effectiveness in some patients.
  • Understanding NSCLC pathobiology is crucial for identifying new therapeutic targets.

Purpose of the Study:

  • To review the oncogenic role of YAP/TAZ in NSCLC, particularly in immune evasion.
  • To explore the potential of targeting YAP/TAZ in combination with immune checkpoint inhibitors.

Main Methods:

  • Literature review of studies investigating YAP/TAZ in NSCLC.
  • Focus on YAP/TAZ's role in tumor immunity and immune evasion.
  • Analysis of therapeutic strategies involving YAP/TAZ inhibition.

Main Results:

  • Yes-associated Protein (YAP) and transcriptional coactivator with PDZ-binding motif (TAZ) are key effectors of the Hippo pathway.
  • YAP/TAZ play significant roles in NSCLC development, progression, and immune evasion.
  • Evidence suggests YAP/TAZ contribute to resistance against current therapies.

Conclusions:

  • YAP/TAZ are critical regulators of tumor immunity in NSCLC.
  • Inhibiting YAP/TAZ may overcome resistance to immune checkpoint inhibitors.
  • Combining YAP/TAZ inhibitors with immune checkpoint inhibitors shows therapeutic promise for NSCLC management.
Keywords:
Yes-associated Protein (YAP)immune checkpoint inhibitorsnon-small cell lung cancer (NSCLC)programmed cell death protein-1 (PD-1)programmed cell death-ligand 1 (PD-L1)transcriptional coactivator with PDZ-binding motif (TAZ)

More Related Videos

Identification of Transcription Factor Regulators using Medium-Throughput Screening of Arrayed Libraries and a Dual-Luciferase-Based Reporter11:32

Identification of Transcription Factor Regulators using Medium-Throughput Screening of Arrayed Libraries and a Dual-Luciferase-Based Reporter

Published on: March 27, 2020

7.0K
Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology07:04

Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology

Published on: May 2, 2025

468

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.7K
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
600
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.0K